TARDBP and amyotrophic lateral sclerosis: Targets that were too generic (such as STAT3) or had already been strongly linked to ALS (through previous extensive research) and therefore no longer qualified as ‘novel’ therapeutic targets (such as TDP-43, SOD1, FUS, C9ORF72, VCP, etc.)were removed from this list in advance.